U.S. Biotech Stock News

NasdaqGS:BRZE
NasdaqGS:BRZESoftware

Is Braze (BRZE) Turning the AI Trust Gap Into a Competitive Edge in Customer Engagement?

Braze recently released its 2026 Global Customer Engagement Review, revealing a “trust gap” between marketers’ confidence in AI and consumers’ real-world experiences, as AI-powered brand interactions become more common. Amid this gap, Braze argues that brands using AI to deliver human-centric, real-time personalization can deepen loyalty, a theme echoed by analysts who still view its platform and integrated CRM capabilities as competitively well positioned despite AI-related...
NYSE:AEM
NYSE:AEMMetals and Mining

New Kirkland Lake Exploration Puts Fresh Focus On Agnico Eagle Mines

Atacama Resources International has acquired the Atacama 3 mineral property near Agnico Eagle Mines' Macassa Mine in the Kirkland Lake region. The company plans to initiate gold exploration activity on the newly acquired property, highlighting fresh interest around an established mining hub. The proximity of Atacama 3 to Macassa could influence Agnico Eagle Mines' local relationships, project planning, and potential collaboration opportunities. Agnico Eagle Mines (NYSE:AEM) sits at the...
NYSE:PPG
NYSE:PPGChemicals

Is PPG Industries (PPG) Attractive After Recent Mixed Returns And Coatings Demand Outlook?

If you are wondering whether PPG Industries at around US$123 per share is offering good value right now, you are not alone. The stock has had mixed returns, with a 2.6% decline over the last 7 days, an 8.2% gain over 30 days, 18.1% year to date, and 11.7% over 1 year. The 3 year and 5 year returns sit at 4.2% and 4.5% declines respectively. Recent news around PPG has focused on its role as a large coatings and materials supplier and how it is positioning its portfolio across construction,...
NYSE:BKU
NYSE:BKUBanks

A Look At BankUnited (BKU) Valuation After Solid Results And Slower Net Interest Income Growth

Recent commentary around BankUnited (BKU) focuses on its solid quarterly results, which have supported recent share price gains, while also highlighting slower net interest income growth and the possibility of a less efficient cost base ahead. See our latest analysis for BankUnited. At a latest share price of $46.70, the 1 day and 7 day share price returns of 5.62% and 6.73% declines contrast with a 90 day share price return of 8.08% and a 1 year total shareholder return of 28.47%. This...
NYSE:ARES
NYSE:ARESCapital Markets

Is Ares (ARES) Using Its New Shelf And CLO To Quietly Rewire Its Funding Playbook?

Ares Management recently filed an omnibus shelf registration covering Class A common stock, preferred stock, debt securities, depositary shares, warrants, purchase contracts and units, giving it broad flexibility to raise capital over time. Ares also priced its second European Direct Lending CLO at over €300 million, underscoring the scale of its direct-lending platform across more than 70 Western European middle‑market borrowers. We’ll now examine how this fresh shelf registration, and the...
NYSE:BFLY
NYSE:BFLYMedical Equipment

Assessing Butterfly Network’s Valuation After Record Q4 Growth And First Positive Operating Cash Flow

Butterfly Network (BFLY) is back on investors’ radar after reporting record fourth quarter revenue, 41% year-over-year growth and its first quarter of positive operating cash flow, supported by its Butterfly Embedded platform and Midjourney partnership. See our latest analysis for Butterfly Network. The share price has been volatile around the recent earnings and guidance, with a 27.18% 7 day share price return reversing sharply into an 18.84% 1 day decline. At the same time, the 1 year total...
NYSE:CNO
NYSE:CNOInsurance

Did CNO’s TechMod Overhaul and Worksite Exit Just Recast CNO Financial Group's (CNO) Efficiency Play?

CNO Financial Group has released its 2025 Form 10-K, outlining past-year operational performance, a planned exit from the Worksite Division’s fee services business by the first half of 2026, and a three-year TechMod program to upgrade its technology infrastructure. An interesting angle for investors is how concentrating on core insurance operations while overhauling technology may reshape CNO’s efficiency profile and operating return on equity over time. Now we’ll explore how CNO’s TechMod...
NYSE:NVT
NYSE:NVTElectrical

Record Revenue and Surging Backlog Might Change The Case For Investing In nVent Electric (NVT)

In recent weeks, nVent Electric reported record Q4 2025 revenue with quarterly sales surpassing US$1.00 billion and full-year sales reaching US$3.90 billion, while also affirming a regular quarterly dividend of US$0.21 per share payable on May 8, 2026. The company’s expanding product set in liquid cooling and infrastructure solutions, together with a tripled order backlog of US$2.30 billion, underlines how exposed it is to long-term demand trends in data centers and renewable energy-related...
NYSE:VVX
NYSE:VVXAerospace & Defense

A Look At V2X (VVX) Valuation After Record Results And Major T 6 Aircraft Contract Wins

V2X (VVX) is back in focus after reporting record quarterly revenue and earnings, locking in a US$4.3b T-6 Aircraft award and other billion-dollar contracts, and issuing upbeat 2026 revenue guidance. See our latest analysis for V2X. Those contract wins and upbeat 2026 outlook sit alongside a 27.16% 90 day share price return and a 48.66% 1 year total shareholder return, which suggests momentum has been building as earnings and backlog news has come through. If V2X’s run has you thinking about...
NasdaqGS:ALNY
NasdaqGS:ALNYBiotechs

Alnylam Phase 1 ALN-4285 Data Highlights Expanding RNAi Platform Potential

Alnylam Pharmaceuticals (NasdaqGS:ALNY) reported a new update on its Phase 1 clinical study of ALN-4285. The RNA based drug targets a novel disease related protein and the company released preliminary safety and pharmacokinetic data. The announcement marks an early step in assessing ALN-4285 in human subjects in a clinical setting. Alnylam, a company focused on RNA based medicines, has been building a pipeline of investigational therapies that aim to modulate disease related proteins at the...
NasdaqGS:ROST
NasdaqGS:ROSTSpecialty Retail

Does Robust Q3 Growth And New Stores Change The Bull Case For Ross Stores (ROST)?

In recent months, Ross Stores reported solid third-quarter 2025 results with 10% total sales growth, 7% comparable store gains, an 11.6% operating margin despite tariff pressures, and the completion of its 90-store 2025 expansion program. At the same time, Ross’s off-price model is benefiting from increased access to discounted inventory amid retail bankruptcies, supporting the company’s margin structure and reinforcing positive sentiment among research analysts and independent...
NYSE:OXY
NYSE:OXYOil and Gas

Is Occidental Petroleum (OXY) Pricing Reflect Long Term Value After Mixed Share Performance

If you are wondering whether Occidental Petroleum's current share price really reflects what you are getting for your money, this article walks through the numbers so you can judge the value for yourself. The stock last closed at US$53.08, with returns of 2.4% over 7 days, 18.4% over 30 days, 25.2% year to date, 11.1% over 1 year, negative 8.9% over 3 years and 80.4% over 5 years. This gives you a mixed picture to keep in mind as you weigh the valuation. Recent coverage of Occidental has...
NYSE:OTIS
NYSE:OTISMachinery

A Look At Otis Worldwide (OTIS) Valuation After Launch Of Arise MOD Elevator Modernization Packages

Otis Worldwide (OTIS) has introduced its Arise MOD Prime and Arise MOD Plus elevator modernization packages in North America, giving building owners more choice over how they update low to mid rise residential and commercial elevators. See our latest analysis for Otis Worldwide. At a share price of US$92.56, Otis has a 30 day share price return of 4.47%. Its 1 year total shareholder return shows a 5.52% decline, which contrasts with a 54.07% total shareholder return over five years and...
NasdaqCM:ABTC
NasdaqCM:ABTCSoftware

American Bitcoin (ABTC) Revenue Surge With FY 2025 Loss Tests Bullish Growth Narratives

American Bitcoin (ABTC) has closed out FY 2025 with Q4 revenue of US$78.3 million and a basic EPS loss of US$0.06, alongside trailing twelve month revenue of US$185.2 million and EPS of US$0.17. Over the past few quarters the company has seen revenue move from US$11.6 million in Q3 2024 to US$12.3 million in Q1 2025, US$30.3 million in Q2 2025, US$64.2 million in Q3 2025 and US$78.3 million in Q4 2025, while quarterly EPS has ranged from a loss of US$1.99 in Q1 2025 to a profit of US$0.06 in...
NYSE:APLE
NYSE:APLEHotel and Resort REITs

A Look At Apple Hospitality REIT (APLE) Valuation After Its Earnings Beat And Updated Outlook

Apple Hospitality REIT (APLE) is back in focus after reporting fourth quarter and full year 2025 results that came in ahead of earnings and revenue expectations, despite softer midweek and government travel demand. See our latest analysis for Apple Hospitality REIT. The latest earnings beat has come against a backdrop of mixed returns, with a 6.8% 1 month share price return and a 3.1% 3 month share price return. The 1 year total shareholder return is a 10.4% loss despite regular monthly...
NasdaqGS:CHDN
NasdaqGS:CHDNHospitality

Is Churchill Downs’ Mixed 2025 Earnings and New Marshall Yards Venue Altering The Investment Case For Churchill Downs (CHDN)?

Churchill Downs Incorporated recently reported fourth-quarter and full-year 2025 results, with revenue rising to US$665.9 million in the quarter and US$2.93 billion for the year, while net income and earnings per share eased compared with 2024. Alongside earnings, the company continued to build out its historical horse racing footprint, including the February 2026 opening of the Marshall Yards Racing & Gaming venue in Kentucky, underlining management’s focus on expanding higher-margin racing...
NasdaqGS:MNST
NasdaqGS:MNSTBeverage

Monster Beverage (MNST) Margin Expansion Reinforces Bull Narratives Despite Rich P/E

Monster Beverage (MNST) closed out FY 2025 with fourth quarter revenue of US$2.1 billion and basic EPS of US$0.46, alongside trailing twelve month revenue of US$8.3 billion and EPS of US$1.95 that followed earnings growth of 26.3% over the last year. Over recent periods, the company has seen quarterly revenue move from US$1.9 billion in Q3 2024 to US$2.0 billion in Q4 2024, then to US$1.9 billion in Q1 2025 and US$2.1 billion in both Q2 and Q4 2025, while basic EPS shifted from US$0.38 in Q3...
NasdaqGS:IONS
NasdaqGS:IONSBiotechs

Ionis FDA And Phase 3 Updates Reframe Rare Disease Valuation Story

Ionis Pharmaceuticals (NasdaqGS:IONS) received FDA Priority Review for olezarsen in severe hypertriglyceridemia, indicating an expedited regulatory timeline. New Phase 3 analyses for DAWNZERA, an RNA targeted therapy for hereditary angioedema, are scheduled for presentation at a major scientific forum. These developments focus on two rare disease programs that are central to Ionis’s drug development efforts. Ionis Pharmaceuticals focuses on RNA targeted medicines, with a portfolio that...
NYSE:NIO
NYSE:NIOAuto

NIO Expands EV Tech Stack With GeniTech Funding And Bosch Partnership

NIO (NYSE:NIO) has received its first major external funding for its intelligent driving chip unit GeniTech (Shenji) from Chinese investors. The company has created a new subsidiary focused on battery technology. NIO has also entered into a new cooperation with Bosch around smart electric vehicle technologies. NIO, listed on the NYSE under the ticker NIO, is known for its premium smart electric vehicles and in-house technology efforts. The fresh capital for GeniTech, together with the new...
NYSE:BRSL
NYSE:BRSLHospitality

Brightstar Lottery Board Shifts Test Capital Returns And Italy Growth Plan

Brightstar Lottery (NYSE:BRSL) has appointed Mariangela Zappia, an international diplomat, as an independent director to its board. The company has announced that CFO Max Chiara will not stand for board re election, with his departure expected after the upcoming shareholder meeting. Brightstar recently secured a nine year renewal of the Italy Lotto licence, supporting a multiyear capital allocation plan and expansion initiatives. Brightstar Lottery, listed on the NYSE under ticker BRSL,...
NYSE:FR
NYSE:FRIndustrial REITs

A Look At First Industrial Realty Trust’s Valuation After Land & Buildings’ Activist Letter And Board Challenge

Why the activist letter matters for First Industrial Realty Trust (FR) On February 26, Land & Buildings Investment Management publicly challenged First Industrial Realty Trust (FR), criticizing its boardroom culture and urging changes it says are needed to address the REIT’s trading discount and unlock more value. See our latest analysis for First Industrial Realty Trust. At a share price of US$63.14, First Industrial Realty Trust has logged an 11.03% 1 month share price return and a 14.42% 1...
NasdaqGS:OLMA
NasdaqGS:OLMABiotechs

Olema Pharmaceuticals (OLMA) Valuation Check After Recent Share Price Volatility

Olema Pharmaceuticals (OLMA) has been drawing attention after recent share price swings, with the stock at US$24.20 and mixed returns over the past month, past 3 months, and year to date, prompting fresh investor scrutiny. See our latest analysis for Olema Pharmaceuticals. While the recent 1 day and 30 day share price returns show modest declines from US$24.20, the very large 1 year and 3 year total shareholder returns suggest earlier optimism around Olema Pharmaceuticals is now being...
NYSE:ECG
NYSE:ECGConstruction

Why Everus Construction Group (ECG) Is Up 11.8% After Record 2025 Results And Higher 2026 Guidance

In February 2026, Everus Construction Group, Inc. reported fourth-quarter 2025 sales of US$1,011.47 million and net income of US$55.28 million, alongside full-year 2025 sales of US$3.75 billion and net income of US$201.77 million, and issued 2026 revenue guidance of US$4.1 billion to US$4.2 billion. Management also underscored that Everus is actively pursuing accretive acquisitions, backed by a strong balance sheet, expanded corporate development capabilities and a broader M&A pipeline...
NYSE:DOLE
NYSE:DOLEFood

Dole’s Veggie Exit, Buyback and Dividend Moves Might Change The Case For Investing In DOLE

Dole plc has reported fourth-quarter 2025 sales of US$2,366.16 million with a net loss of US$2.66 million, alongside full-year 2025 sales of US$9,172.91 million and net income of US$51.32 million, while affirming a US$0.085 per-share quarterly dividend and completing a 300,000-share buyback. Beyond the headline figures, Dole exited its Fresh Vegetables division, authorized up to US$100 million of share repurchases, and is targeting at least US$400 million of adjusted EBITDA for 2026,...